Mereo BioPharma Group plc

Transaction in Own Shares • Oct 31, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9223F

Mereo BioPharma Group plc

31 October 2018

Mereo BioPharma Group plc

("Mereo" or the "Company")

Total Voting Rights

London, 31 October 2018 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, confirms that it has issued 85,222 new ordinary shares of £0.003 each in the capital of the Company (the "New Shares") pursuant to an exercise of employee share options ("Options Exercise").

The New Shares to be issued pursuant to the Options Exercise have already been admitted to trading on AIM ("Admission") under the Company's block listing announced on 3 September 2018.

Following the issue of the New Shares, the Company will have a total of 71,240,272 ordinary shares of £0.003 each in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Mereo BioPharma Group plc	+44 (0)333 023 7300
Denise Scots-Knight, Chief Executive Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated Adviser and Broker)	+44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker)	+44 (0)20 7653 4000
Rupert Walford Jamil Miah
FTI Consulting (Public Relations Adviser)	+44 (0)20 3727 1000
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations Advisor to Mereo Biopharma)	+01 (0) 212 213 0006
Lisa Burns
Ami Bavishi

About Mereo

Mereo is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. The portfolio currently consists of four clinical-stage product candidates, each of which were acquired from large pharmaceutical companies: BPS-804 (setrusumab) for the treatment of osteogenesis imperfecta ("OI"); MPH-966 (alvelestat) for the treatment of severe alpha-1 antitrypsin deficiency ("AATD"); BCT-197 for the treatment of acute exacerbations of chronic obstructive pulmonary disease, ("AECOPD"); and BGS-649 for the treatment of hypogonadotropic hypogonadism ("HH") in obese men. Each of the Company's product candidates has generated positive clinical data for Mereo's target indication or in a related indication. The Company's strategy is to selectively acquire product candidates that have already received significant investment from pharmaceutical companies and that have substantial preclinical, clinical and manufacturing data packages. Since inception the Company has commenced large, randomized, placebo-controlled Phase 2 clinical trials for all four of the product candidates and has previously announced positive top-line results from two of its clinical trials: a Phase 2 trial with BCT-197 in December 2017 and a Phase 2b dose-ranging study with BGS-649 in March 2018.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVRWGGAWUUPRGAG